Erasca, Inc. announced the termination of its Chief Operating Officer, Nicholas Chetwyn, effective November 2, 2026, as part of a leadership realignment to support its RAS-targeting programs. Following this announcement, Erasca's stock price fell nearly 10%, prompting an investigation by Pomerantz LLP into potential securities fraud or other unlawful practices by the company and its officers. Investors affected by this development are encouraged to contact the law firm for possible class action participation. This investigation highlights concerns about corporate governance and could impact Erasca's future operations and investor confidence.
Erasca's stock price on Pluang dropped 12.81% to USD 13.00 as of Nov 06, 2026 07:51 WIB, reflecting significant market reaction. The company holds a market cap of $5.21 billion and a 52-week high of $22.47. This sharp decline follows recent leadership changes and the investigation by Pomerantz LLP, underscoring investor concerns about the company's governance and future prospects.
Tango Therapeutics and Erasca have started a Phase 1/2 clinical trial testing the combination of oral PRMT5 inhibitor vopimetostat with pan-RAS molecular glue ERAS-0015. The trial targets patients with MTAP-deleted pancreatic ductal adenocarcinoma an...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
